Newsroom

Placeholder

Marcia Woolley recognized for 30 years with TriCore


03/14/2019

Marcia Woolley recognized for 30 years with TriCore

Read More
Placeholder

Kim Hedrick Named Vice President of Business Development


01/09/2019

TriCore Reference Laboratories is pleased to announce and welcome Kim Hedrick as the Vice President of Business Development.

Read More
Placeholder

TriCore Announces Steve Ayer as Chief Information Officer


05/25/2018

TriCore Announces Steve Ayer as Chief Information Officer

Read More
Placeholder

TriCore Announces Renee Ennis as Chief Financial Officer


03/21/2018

TriCore Reference Laboratories is pleased to announce Renee Ennis as Chief Financial Officer, effective April 23, 2018.

Read More
Placeholder

TriCore Announces Dr. Michael Crossey as Chief Executive Officer & President


03/15/2018

TriCore Announces Dr. Michael Crossey as Chief Executive Officer and President

Read More
Placeholder

Dr. Nick Dayan, CAO of TriCore Reference Laboratories, named chair and Mark Fidel, co-founder of RiskSense, named vice-Chair of March for Babies


10/16/2017

Dr. Nick Dayan, CAO of TriCore Reference Laboratories, named chair and Mark Fidel, co-founder of RiskSense, named vice-Chair of March for Babies

Read More
Placeholder

TriCore's First Chief Scientific Officer


08/14/2017

Albuquerque-based TriCore Reference Laboratories has established a new executive role to focus on research, the company announced.

Read More

TriCore in the News

Companies Focus on Helping Labs do More with Less

With no end in sight to the lab workforce shortage, vendors aim to fill the gap

AACC,04/09/2019

Practical challenges in peripheral blood smear evaluation

Unlike high-count monoclonal B-cell lymphocytosis, low-count MBL has a limited chance of progression to CLL and thus there is no need for follow-up. And a definitive diagnosis of T-cell large granulocytic leukemia requires demonstration of clonality. Those and other points were made in a CAP18 session on practical challenges in peripheral blood evaluation.

CAP Today,03/25/2019

Improving the Delivery of Healthcare through Clinical Diagnostic Insights: A Valuation of Laboratory Medicine through "Clinical Lab 2.0"

As healthcare payment and reimbursement begin to shift from a fee-for-service to a value-based model, ancillary providers including laboratories must incorporate this into their business strategy. Laboratory medicine, while continuing to support a transactional business model, should expand efforts to include translational data analytics, proving its clinical and economic valuation. Current literature in this area is limited.

Journal of Applied Laboratory Medicine,03/05/2019

Driving Strategic Growth with an Enterprise Laboratory

Summary of webinar panel discussion with laboratory leaders regarding maximizing the strategic value of labs through solutions that provide standardization, efficiency, and cost savings, and through constant innovation.

www.bullseyeresources.com,01/22/2019

Recent Tweets

Follow us on Twitter

Contact Us

Beth Bailey
beth.bailey@tricore.org